Compare VTRS & FIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | FIG |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | United States |
| Employees | 30000 | 1886 |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 15.2B |
| IPO Year | 2019 | N/A |
| Metric | VTRS | FIG |
|---|---|---|
| Price | $13.75 | $25.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $13.00 | ★ $50.50 |
| AVG Volume (30 Days) | 9.5M | ★ 14.4M |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,299,900,000.00 | N/A |
| Revenue This Year | $3.36 | $31.18 |
| Revenue Next Year | $1.87 | $20.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.85 | $19.85 |
| 52 Week High | $16.47 | $114.29 |
| Indicator | VTRS | FIG |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 42.43 |
| Support Level | $12.92 | $19.85 |
| Resistance Level | $16.38 | $31.10 |
| Average True Range (ATR) | 0.44 | 1.65 |
| MACD | -0.20 | -0.26 |
| Stochastic Oscillator | 12.93 | 7.19 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.